Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain
Unknown statusNot applicableNCT04786145
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will provide information on the effectiveness of cryoneurolysis for patients with facet joint pain syndrome, and help to establish whether cryoneurolysis should be implemented in clinical practice for this patient population.
Study details
- Official title
- Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain - a Single-blinded Randomized Controlled Trial
- Conditions
- Chronic Low-back Pain
- Facet Joint Pain
- Degeneration Lumbar Spine
- Facet Joint Syndrome
- Back Pain Lower Back Chronic
- Interventions
- Procedure: Cryoneurolysis
- Procedure: Radiofrequency ablation
- Procedure: Placebo
- Sponsor
- University of Aarhus
- Collaborators
- Aarhus University Hospital
- Start date
- 2020-02-15
- Primary completion
- 2022-10-01
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Low-back pain from facet joint syndrom (facet joint pain) \> 3 months' duration with or without neuropathic pain component. * Low-back pain on Numeric Rating Scale ≥ 4 Exclusion Criteria: * Presence of nerve root or spinal canal compression; signs of inflammatory or erosive processes in the spine verified on magnetic resonance imaging (MRI). * Neurological deficits i.e. symptoms of nerve root compression; tingling, numbness, weakness/ paresis, and reflex loss in the lower extremities. * Major co-morbidity. * Anti-thrombotic or anti-platelet treatment which cannot be paused for a week. * Active malignancies. * Chronic inflammatory disease. * Known severe psychiatric disease. Patients with mild and well-treated depression and anxiety are not excluded.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04786145